Plocamium Global Insights

Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients

10 min · 23. maj 2026
episode Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients cover

Description

Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa

Comments

0

Be the first to comment

Sign up now and become a member of the Plocamium Global Insights community!

Get Started

1 month for 9 kr.

Then 99 kr. / month · Cancel anytime.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

All episodes

429 episodes